With a major funding round in its sights this year, Moncton-based medtech company Picomole is aiming to have a product on the market in 2024 that can detect lung cancer from a single breath sample.
The technology has been in development for about a decade, and the company got a major boost from a $6.5 million funding round in 2019. Now the 22-member team is developing the product in preparation for a launch in the New England market in about three years.
The vision is to use the device for the early detection of several forms of cancer and other diseases, but the first mission is to use it
